Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

Posted by George Bondi on May 15th, 2026

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) VP Meredith Cook sold 500 shares of the company’s stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $78.16, for a total value of $39,080.00. Following the transaction, the vice president directly owned 78,390 shares of the company’s stock, valued at approximately $6,126,962.40. This represents a 0.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

On Monday, April 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $77.95, for a total value of $38,975.00.
On Friday, March 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $72.62, for a total value of $36,310.00.

ANI Pharmaceuticals Trading Down 1.6%

NASDAQ:ANIP opened at $79.58 on Friday. The stock has a market cap of $1.78 billion, a P/E ratio of 20.15 and a beta of 0.46. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. ANI Pharmaceuticals, Inc. has a 1 year low of $56.71 and a 1 year high of $99.50. The stock has a 50-day simple moving average of $77.26 and a 200-day simple moving average of $80.50.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last announced its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.77. The firm had revenue of $237.46 million during the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The business’s revenue was up 20.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ANIP shares. Guggenheim upped their target price on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 15th. Finally, Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $107.33.

Check Out Our Latest Analysis on ANIP

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of ANI Pharmaceuticals by 2.2% during the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after buying an additional 27,598 shares in the last quarter. State Street Corp raised its stake in shares of ANI Pharmaceuticals by 2.2% during the 4th quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock worth $57,405,000 after buying an additional 15,496 shares in the last quarter. UBS Group AG raised its stake in shares of ANI Pharmaceuticals by 45.8% during the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after buying an additional 185,172 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of ANI Pharmaceuticals by 19.3% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock worth $43,399,000 after buying an additional 91,153 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of ANI Pharmaceuticals by 8.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock worth $40,843,000 after buying an additional 43,523 shares in the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

Positive Sentiment: ANI Pharmaceuticals posted a strong first quarter, with EPS of $2.05 beating estimates of $1.28 and revenue of $237.46 million topping expectations, while management also guided FY2026 EPS to $9.19-$9.69, reinforcing the company’s growth story.
Positive Sentiment: Analyst sentiment remains favorable, with recent upgrades and a consensus “Moderate Buy” rating plus an average price target above the current trading range, which can support longer-term confidence in ANIP.
Neutral Sentiment: ANI Pharmaceuticals updated its investor presentation and highlighted non-GAAP metrics, a routine corporate communication that does not appear to materially change the near-term outlook. ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics
Negative Sentiment: CEO Nikhil Lalwani sold 55,000 shares, and other executives and directors also trimmed holdings, including Patrick D. Walsh, Meredith Cook, Ori Gutwerg, and Thomas Andrew Rowland; heavy insider selling can weigh on sentiment even when some trades are pre-planned.
Negative Sentiment: A separate filing reported that Global Alpha sold 229,000 ANIP shares worth about $17.9 million, adding to concerns that a large investor may be reducing exposure. Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million

About ANI Pharmaceuticals

(Get Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.